3500 tons of HMO, 107 billion PBAT, 100 billion bio-based materials... Bio-manufacturing capacity surges!
The bio-manufacturing industry is entering a period of dense capacity deployment and rapid expansion.
From a single corn kernel to a capsule, from the laboratory to mass production, key projects across the country are launching or coming online one after another. The bio-manufacturing industry is taking root at an unprecedented pace,Synthetic biology, bio-based materials, and biopharmaceuticalscontinuously breaking through in multiple core sectors.
2026 will be the year of full-scale bio-manufacturing capacity explosion, worth continued attention!
[ Synthetic Biology ]
The "last mile" from lab to scale-up
Huangshan Tongxi Bio: Delivery of the World's Largest HMO Facility
4 25,Huangshan Tongxi Biotechnology Co., Ltd.'s state-of-the-art HMO production facility, the world's largest for human milk oligosaccharides, has been officially completed and handed over in Huangshan District.With the launch of this new production line, annual capacity will reach 3500 tons, solidifying our position as the world's leading single HMO manufacturing facility.
This HMO project is a cornerstone of Huangshan District's efforts to cultivate new quality productive forces and build a green biomanufacturing industrial cluster. It will continue to drive regional industrial upgrading and propel high-quality local economic development.
Xinhong Bio: 7.5 billion yuan industrial park breaks ground in Jingjiang
On 4 22, the Xinhong Biopharmaceutical Manufacturing Industrial Park project, with a total investment of 7.5 billion yuan, broke ground at the Chengnan Industrial Park in Jingjiang Economic and Technological Development Zone. The project covers an area of 111 mu.Focus on R&D and manufacturing of precision supplements, cosmetics and medical devices, pharmaceutical intermediates, and Class II and III medical devices.Connects the full innovation chain from gene design and strain construction to product isolation and purification.
Hongmu Bio: Hefei Synthetic Biology Project Settles in High-Tech Zone
On 2 4, Hongmo Biotechnology (Shanghai) Co., Ltd. (referred to as "Hongmo Bio") secured over 100 million RMB in strategic funding, with its synthetic biology project established at Hefei High-tech Zone. The round was led by Anhui Venture Capital, with participation from Hefei Industrial Investment, Hefei High-tech Investment, and Construction Investment Group. Funds will be allocated to increase R&D investment, expand production capacity, and strengthen channel development.
Hongmo Bio is an innovative biomanufacturing enterprise incubated by the Mengniu Group.Focused on the independent R&D and commercialization of HMOs, dedicated to breaking the long-standing monopoly of international brands in this field.
[ Biopharmaceutical CDMO & Biologics Manufacturing ]
High-end capacity accelerating release
WuXi Bio: Chengdu Microbial Commercial Production Base to Launch by Year-End
On 4 24, WuXi Biologics' commercial-scale microbial production facility in Wenjiang, Chengdu achieved completion of its main structure and arrival of key equipment in 4, with GMP production on track for year-end 2026.
The base covers an area of 95000 square meters and will be equipped with 15000-liter fermenters, with an annual raw liquid production capacity of 110 batches.Maximum future fermentation capacity scalable to 60000 liters. It will also establish a joint venture with Vitas Pharmaceuticals in China.First dual-chamber freeze-dried formulation production lineThe annual production capacity of the dosage form is expected to exceed 1000 million units.
Longi Bio: Lin'an Antibody Drug Production Base to Begin Trial Production by End of 7
Zhejiang Longi Biotechnology Co., Ltd.'s new production and R&D building, located in Lin'an Tianmu Medical Port, is expected to begin trial production by the end of 7 this year.
Two production lines have been established.One pilot line, one commercial production lineIt can form bubbles.
Step Pharmaceutical: Participates in HIV Vaccine Production Project
On 5 8, Zhejiang Tianyuan, a subsidiary of Chongqing Buzheng Pharmaceutical, received an official notice from the National Health Commission to launch a major national science and technology project: "Development of a Multivalent Antibody-Based Preventive HIV Vaccine." The specific task involves the production of the HIV vaccine and submission for Phase I clinical trials. The project will run from 2026 3 to 2031 2 and holds strategic significance for controlling major infectious diseases in China.
[Bio-based New Materials]
Green alternatives see a surge in production capacity
Ruixun Biomaterials: Mechanical Completion of Bio-based THF/PTMEG Plant
On 4 20, RuiXun Bio-Materials' first commercial production base for carbon 4 platforms, located in Qidong, Jiangsu, achieved mechanical completion. The facility represents a total investment of 100 billion RMB and is planned for three-phase construction, with a future target capacity of 50 thousand tons of bio-based materials annually.
The first-phase bioTHF and bioPTMEG commercial production projects are expected to begin initial operations in the second half of 2026.The base uses non-food agricultural byproducts as raw materials., helping the materials industry reduce its reliance on fossil-based products.
Industrialization of Bamboo Fiber: 50 Billion Yuan Project Settles in Lianzhou, Guangdong
On 4 17, a bamboo fiber industrialization project with a total investment of 50 billion yuan was launched in Lianzhou City, Guangdong Province. The project aims to establish the region as a "highland for bio-based materials in South China" and inject strong momentum into Lianzhou's development as a modern central city at the intersection of Guangdong, Hunan, and Guangxi.Bridge the supply gap for high-end bio-based fibers in South China。
Inner Mongolia Dongjing Zhongke: 107 billion yuan PBAT project breaks ground
On 3/26, the PBAT biodegradable polyester project, with a total investment of approximately 107 million yuan, broke ground in Wuda High-tech Zone, Wuhai City, Inner Mongolia. The project includes an annual production capacity of 120 tons of PBAT biodegradable polyester, 300 tons of PBAT modified materials, and 200 tons of fully biodegradable products.
The project leverages the BDO industry foundation, achieving local self-sufficiency for core raw materials to establish a "Coal — BDO — PBAT — Modified Materials — End Productscomplete closed-loop industrial chain.
[Biofermentation and Raw Material Base]
Strengthen the foundation of the industrial chain
Tsingtao Brewery: Phase I of Biomanufacturing Project Breaks Ground, Aiming to Create a Zero-Carbon Park
Construction has begun on the first phase of Tsingtao Beer's bio-manufacturing project in Pingdu City, with a total investment area of 1.76 square meters. The project will utilize proliferating yeast and spent grain generated during production, applying advanced bio-extraction technologies developed by the Tsingtao Beer National Key Laboratory for deep processing. The entire park is scheduled to be completed and put into operation in 2026, Month 10.Build zero-carbon parks and waste-free factories powered by non-fossil energy.。
Hainan Zhuoyue Biotech: Intelligent Industrial Base Begins Operations
On 4 25, the commissioning ceremony for Hainan Zhuoyue Biotechnology Co., Ltd.'s Intelligent Industrial Base was held in Chengmai County's Laocheng Tech New City. The Intelligent Manufacturing Center is equipped with 5 smart production lines, achieving an hourly output of 6000 to 7000 bottles.Microbial Fermentation Production LineDesigned to exceed an annual fermentation capacity of 5000 tons, enabling full-process digital traceability from raw material intake to finished goods shipment.
Tuoketuo County: 30 biomanufacturing companies cluster here, from corn to capsules
Located at the golden corn belt of latitude 40 in Tuoketuo County, Hohhot, the region produces up to 600 tons of corn annually within a 200-kilometer radius. The county has already gathered 30 upstream and downstream bio-manufacturing enterprises.Chlortetracycline, Coenzyme Q10, Astaxanthin, and other 6 products rank among the world's leading in production capacity.Truly achieving a stunning transformation from a single kernel of corn to a single capsule.
From lab to factory, from technology to capacity: the 2026 year surge in bio-manufacturing capacity deployment is both a hallmark of industry maturity and a microcosm of China's intelligent green transformation. In the future, as a wave of flagship factories comes online,Biomanufacturing will be deeply integrated into pharmaceuticals, materials, food, and agriculture.Continuously unlock trillions in market potential to support the achievement of "Dual Carbon" goals.
Based on this,The 2026 BIO-TECH Manufacturing Industry Expo will be held grandly in Shanghai from 8/27-28.This exhibition is organized by Yimao Medical. Invited guests will be present on-site, including:2000+Attendee,150+ Speaker,50+Premium exhibitors, featuring "Exhibitions - Products - Conferences - PartnershipsFour core modules focused on "breakthroughs in fundamental research and cross-sector industrialization," establishing a benchmark event for the entire bio-manufacturing value chain.
Whether you are an entrepreneur, investor, technical expert, or procurement decision-maker in the bio-manufacturing sector, this exhibition offers a platform to explore the latest policy trends and industry developments, connect with top-tier capital and high-quality projects, and showcase cutting-edge technologies and innovative products.
